Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pyrotinib plus Trastuzumab in Small HER2+ Breast Cancer
NCT04158856Phase 2Not yet recruiting
- Start
- Jun 2020
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer. Primary endpoint: Disease-free Survival at 5 years. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04158856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158856.